There’s no single figure, because the cost tracks what the surgery actually involves. How much lung is removed, a small wedge or a full lobe, sits at the centre of it. The hospital, the surgeon’s experience, whether lymph nodes are cleared, and how long the stay runs all shape the total. VATS often works out lower overall than open surgery, thanks to the shorter stay. An accurate number comes from a consultation.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “People want one number, but the honest answer depends on the operation. Removing a small wedge is different from a full lobectomy with node clearance. What I tell patients is that VATS often costs less than open surgery over the whole episode, because they’re in hospital days rather than a week and back on their feet faster. Comparing only the operating fee misses that. The real figure comes from looking at the actual case.”

Several factors decide where a particular VATS case lands, and they vary between patients.

• Extent of resection : A small wedge resection is a lesser operation than a full lobectomy or pneumonectomy. How much lung comes out moves the cost directly.
• Hospital and facility : A dedicated surgical oncology setup differs from a general hospital. The facility cost reflects the team, theatre and post-operative care involved.
• Surgeon experience : A high volume thoracic surgeon with a long VATS track record is priced differently from an occasional one, and that reflects lower complication rates.
• Node dissection : Whether lymph nodes are cleared, and how extensively, adds to the operating time and the cost of the procedure.

The full scope of what’s involved sits within lung cancer treatment, and which elements a patient needs is what drives their particular cost.

Looking only at the operating fee misses where VATS often saves money across the whole treatment.

• Shorter stay : VATS patients often go home in three to four days rather than a week. Fewer hospital days is a direct, meaningful saving.
• Faster recovery : Getting back to normal activity, and to work, sooner has a real economic value that an operating quote alone never captures.
• Fewer complications : Smaller incisions mean lower rates of wound problems and infection. Avoiding a complication avoids the cost of treating it.
• Sooner to next steps : A quicker recovery means any adjuvant treatment can start on time, keeping the whole plan efficient.

Understanding what the operation actually involves, covered in our guide on VATS surgery, makes these cost differences much clearer.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He performs VATS lung surgery with the volume and judgement it demands, and starts every case with accurate staging so that any cost estimate reflects what the patient genuinely needs. The approach treats an honest, case specific figure as part of good care, rather than a vague range that helps no one plan.

Value in lung cancer surgery isn’t the lowest quote, it’s the right operation done well, with a recovery that keeps the total cost sensible. VATS delivers exactly that for suitable patients, a thorough cancer operation with a shorter stay and fewer complications than open surgery. A clear consultation that maps the plan and its cost lets a patient and family prepare properly, without the surprises that come from comparing incomplete numbers.

References

1. Cost and outcomes of VATS versus open lobectomy — National Library of Medicine
2. Recovery and hospital stay after VATS lobectomy — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

The best lung cancer surgeon isn’t the one with the most advertising, it’s the one with the numbers behind them. What actually matters is how many lung cases they do, whether they offer VATS and robotic surgery as well as open, and whether they work within a proper multidisciplinary team. Volume builds judgement. Minimally invasive skill means gentler recovery. A team means better decisions. Those are the real markers.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients ask me how to find the best surgeon, and my honest answer is to ignore the marketing and ask about numbers. How many lung resections does this surgeon do a year? Do they offer VATS and robotic, or only open? Is there a tumour board reviewing the case? A surgeon who does this at real volume, within a team, is what you want. The title matters far less than the track record.”

These are the things that genuinely separate a strong lung cancer surgeon from an average one.

• Case volume : A surgeon doing many lung resections a year has the anatomical familiarity and judgement that lower complication rates and cleaner outcomes.
• Minimally invasive skill : Offering VATS and robotic surgery, not just open, means patients get the faster, gentler recovery those approaches allow when suitable.
• Honest staging : A good surgeon assesses resectability truthfully, neither overpromising surgery that won’t help nor ruling out an operable cancer too quickly.
• A real team : Working within a tumour board, where oncologists, radiologists and pathologists review cases together, produces better plans than any one person alone.

These standards shape genuine lung cancer treatment, where the surgeon’s experience and setup decide much of the outcome.

Beyond credentials, a few practical questions reveal how experienced a surgeon really is.

• Ask the numbers : How many cases of your specific lung cancer does this surgeon do each year? A confident, specific answer tells you a lot.
• Ask the approach : Do they offer minimally invasive surgery for your case, or default to open? The full range signals a serious centre.
• Ask about the team : Is your case reviewed by a multidisciplinary board? Team based planning is a mark of proper cancer care.
• Look past the noise : The most advertised name isn’t automatically the most skilled. The right questions matter more than search rankings.

This is the same framework covered in our guide on choosing a cancer surgeon, applied specifically to lung cancer surgery.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He performs lung cancer surgery using both VATS and robotic thoracic techniques, with over 15 years of minimally invasive oncology experience and more than a thousand such operations behind him. As founder of MACS Clinic, he works within a multidisciplinary setup where every case is planned by a team. That combination of volume, technique and teamwork is exactly what the criteria above describe.

Choosing a lung cancer surgeon comes down to matching the person to those standards, not to a headline. Dr. Nayak sees patients directly, assesses resectability honestly, and offers the full range of surgical approaches rather than a single default. For a patient weighing where to go in Bangalore, the useful measure isn’t who claims to be best, it’s who does this work at real volume, within a team, with a track record to show for it.

References

1. Surgeon volume and outcomes in lung cancer resection — National Library of Medicine
2. Minimally invasive thoracic surgery outcomes — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

It isn’t one against the other. The choice comes down to what molecular testing finds in the tumour. If the cancer carries a targetable mutation, like EGFR or ALK, targeted therapy usually works better and is easier to tolerate. If there’s no such mutation, chemotherapy is the answer. So the tumour’s genetics decide, not a general preference. Testing first, treatment second.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients often ask me which is better, as if one always wins. But it depends entirely on the tumour. If molecular testing shows a mutation we have a drug for, targeted therapy is remarkable, high response, fewer side effects. If there’s no target, chemotherapy remains essential and effective. The mistake is choosing before testing. You can’t pick the right tool until you know what you’re dealing with.”

The two treatments work in fundamentally different ways, which is why testing matters so much.

• Targeted therapy : It blocks a specific fault driving the cancer, like a mutated EGFR gene. Precise, and mostly sparing of healthy cells.
• Chemotherapy : It attacks all rapidly dividing cells. Effective and broad, but it hits healthy fast growing cells too, which causes the familiar side effects.
• The mutation gate : Targeted therapy only works if the tumour has the matching mutation. No target, no benefit, which is why testing comes first.
• Chemo works regardless : Chemotherapy doesn’t need a mutation. It works across cancer types, which keeps it essential when there’s nothing to target.

Choosing correctly is central to good lung cancer treatment, and it starts with knowing the tumour’s molecular profile.

Here’s how the two line up side by side.

• When targeted wins : In a tumour with a matching mutation, targeted therapy often far outperforms chemotherapy, with much higher response and gentler side effects.
• When chemo is essential : No targetable mutation means chemotherapy is the right, effective choice. It remains a cornerstone of lung cancer treatment.
• Not always either or : Sometimes they’re combined or sequenced, chemo then targeted, or both together, depending on the tumour and stage.
• Testing decides : None of this works without molecular testing. It’s the step that turns a guess into a precise, personalised treatment plan.

All of this depends on the right cancer testing, which reveals the mutations that determine which treatment a patient actually needs.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He works within a multidisciplinary team where molecular testing guides systemic treatment, so the choice between targeted therapy and chemotherapy rests on the tumour’s actual biology rather than assumption. The approach insists on proper testing before treatment, since choosing blind is exactly what wastes a patient’s best option.

Modern lung cancer care lives or dies on getting this decision right. A tumour with an EGFR mutation treated with chemotherapy alone misses a far better option, while chemotherapy given for a mutation negative cancer is exactly correct. Reading the molecular profile and matching the treatment to it is what separates precise, effective care from a one size fits all approach. The testing is the key that unlocks the right plan.

References

1. Targeted therapy versus chemotherapy in EGFR-mutant lung cancer — National Library of Medicine
2. Neoadjuvant targeted therapy versus chemotherapy in NSCLC — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

There’s no single price, because the cost depends entirely on what the surgery involves. A straightforward orchiectomy to remove the affected testicle sits at one end. A complex retroperitoneal lymph node dissection, or surgery combined with chemotherapy for advanced disease, sits well above it. The stage, the type of operation and the hospital stay all shape the final figure. An accurate number comes only from a proper consultation.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients always want a single number, and I understand why, but it depends on what the cancer actually needs. Removing the testicle is one operation. Clearing the abdominal lymph nodes is a far bigger one. Add chemotherapy for advanced disease and the picture changes again. I’d rather give someone an honest, case specific estimate than a misleading figure that ignores their actual situation.”

Several factors decide where a particular case lands, and they vary a lot between patients.

• Type of surgery : A radical orchiectomy is a relatively contained operation. An RPLND, clearing the deep abdominal nodes, is far more complex and costs more.
• The stage : Early disease often needs just the one surgery. Advanced disease may need RPLND, chemotherapy or both, which raises the total considerably.
• Surgical approach : Open, laparoscopic or robotic each carry different costs. The minimally invasive routes use more technology but can shorten the stay.
• Hospital stay : A simple orchiectomy means a short stay. Bigger surgery and any complications extend it, and the length of stay feeds directly into cost.

The full range of procedures involved is set out under testicular cancer treatment, and which ones a patient needs is what drives their particular cost.

Testicular cancer treatment is rarely one size fits all, which is why a flat figure misleads.

• Every case differs : Two patients with the same diagnosis can need very different surgery depending on stage and spread. Their costs differ accordingly.
• Added treatments : Chemotherapy, surveillance imaging and follow up may all be part of the plan. Each adds to the overall cost beyond the surgery itself.
• Markers and scans : Tumour markers and CT scans guide treatment throughout. These investigations are part of the journey, not just the operation.
• An estimate beats a guess : A consultation maps out exactly what’s needed, giving a realistic figure rather than a number that may not apply to you.

Understanding why this cancer needs careful staging, covered in our blog on testicular cancer in young men, shows why the treatment, and the cost, is so individual.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He treats testicular cancer across its range, from orchiectomy through to the complex RPLND that clears abdominal spread. The approach starts with accurate staging, since knowing exactly what a patient needs is what allows an honest cost estimate rather than a vague range that helps no one.

Value in cancer surgery isn’t about the lowest price, it’s about the right treatment done well the first time. Testicular cancer is highly curable, and getting the surgery right, matched precisely to the stage, is what protects both the outcome and the budget. A clear consultation that maps the plan and its cost lets a patient and family plan properly, without surprises along the way.

References

1. Radical orchiectomy and treatment cost analysis — National Library of Medicine
2. RPLND in testicular cancer management — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

Single port surgery isn’t better for liver cancer, but it’s an option in selected cases. It uses one small incision instead of several, which looks neater and can mean less wound discomfort. The catch is it’s technically harder, suits only small tumours in favourable spots, and carries a higher hernia risk. For most liver cancers, standard keyhole or robotic resection remains the proven choice. It’s an option, not an upgrade.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “I’ll be straight about this, single port surgery isn’t a better operation for liver cancer, it’s a different access. For a small tumour in the right spot, it works well and leaves a neater scar. But it’s harder to do safely, and the evidence doesn’t show better cancer outcomes. I never trade oncological safety for one fewer incision. The tumour decides the approach, not the cosmetics.”

It’s a refinement of keyhole surgery, narrowing the access down to one point.

• One incision : Instead of several small cuts for separate instruments, everything goes through a single small incision, usually at the navel.
• The appeal : The main draw is cosmetic, a single hidden scar, along with potentially less wound pain than multiple port sites.
• Same operation inside : Once inside, the actual liver resection follows the same principles. The difference is purely in how the surgeon gets there.
• Small tumours only : It works for small, accessible tumours, often in the left lateral part of the liver. Bigger or deeper lesions don’t suit it.

This sits at the far end of laparoscopic cancer surgery, pushing the minimally invasive idea to its limit, but only where it’s genuinely safe.

The benefits are real but narrow, and the limits matter just as much.

• Not proven superior : There’s no solid evidence that single port surgery gives better cancer outcomes than standard keyhole resection. It’s feasible, not superior.
• Technically harder : Working through one port is more demanding. The instruments crowd each other, which is why it needs a very experienced surgeon.
• Higher hernia risk : That single larger incision carries a greater chance of an incisional hernia later than several tiny ones do.
• Narrow use : Only a small slice of liver cancers fit the criteria. For most, multi port or robotic surgery is simply the better, safer call.

What matters most isn’t the number of incisions but whether the cancer is removed properly, which our guide on liver cancer explains when it comes to cure.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He offers the full range of minimally invasive liver surgery and chooses the approach on merit, not novelty, using single port only where it genuinely suits a small, favourable tumour. The approach puts cancer clearance first and cosmetics second, since a neat scar means nothing if the tumour isn’t removed completely.

The honest framing matters here. Single port surgery is a useful tool in a narrow set of cases, not a better operation for liver cancer in general. A surgeon who understands that won’t push it where standard keyhole or robotic resection is the safer, more complete choice. Matching the method to the tumour, and never trading cancer control for appearance, is the judgement that protects the patient.

References

1. Single port laparoscopic hepatectomy safety and feasibility — National Library of Medicine
2. Single incision laparoscopic approach in liver surgery — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

Non-smokers can and do get lung cancer. Around one in ten cases occurs in people who never smoked, enough that if it were counted on its own, it would rank among the more common cancers. The causes are different: radon, air pollution, secondhand smoke, workplace exposures and genetics. It also behaves differently, often striking women and younger people, and frequently carrying mutations that respond well to targeted treatment.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “I’ve had patients look at me in disbelief because they never touched a cigarette in their lives. But roughly one in ten lung cancers is in a non-smoker, and it’s a genuinely different disease. It tends to be adenocarcinoma, often in women, and it frequently carries a mutation we can target directly. That last part is actually good news, because those cancers often respond beautifully to the right drug.”

When lung cancer appears in someone who never smoked, several factors are usually behind it.

• Radon and pollution : Radon gas seeping into homes, and long term air pollution, are major contributors. Both expose the lungs to carcinogens over years.
• Secondhand smoke : Breathing others’ smoke carries real risk. Years of passive exposure at home or work adds up, even without ever smoking yourself.
• Workplace exposures : Asbestos, diesel fumes and certain industrial chemicals raise lung cancer risk independently of smoking, sometimes decades after exposure.
• Genetics : A family history and inherited susceptibility play a bigger role in non-smokers, especially where cancer appeared young in relatives.

Recognising these different causes shapes the lung cancer treatment approach, since a non-smoker’s cancer often needs a different plan from a smoker’s.

Lung cancer in non-smokers isn’t just the same disease without the smoking. It’s genuinely distinct.

• Different type : It’s usually adenocarcinoma, which grows in the outer parts of the lung, rather than the central tumours more typical of smokers.
• Targetable mutations : Non-smoker cancers often carry mutations like EGFR or ALK. Drugs built for these can control the cancer remarkably well.
• Affects women more : For reasons still being studied, non-smoker lung cancer is diagnosed more often in women than in men.
• Better response : Partly because of those mutations, these cancers often respond better to treatment, and the outlook can be more favourable.

The contrast is clearest against the classic pattern, and understanding smoking and lung cancer shows just how different the two really are.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He treats lung cancer in smokers and non-smokers alike, and pays close attention to the non-smoking group where molecular testing and targeted therapy change everything. The approach starts with not dismissing a lung mass just because someone never smoked, since that assumption is exactly what delays these diagnoses.

The important shift with non-smoker lung cancer is recognising it as its own disease. A non-smoker with a lung mass deserves the same thorough workup and molecular testing as anyone else, because the mutation found is often the key to treatment. Reading that correctly, and matching the therapy to the tumour’s biology, is what gives these patients some of the best outcomes in lung cancer care.

References

1. Risk factors for lung cancer among never smokers — National Library of Medicine
2. Lung cancer in never-smokers risk factors and driver mutations — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.